Esperion Therapeutics (NASDAQ:ESPR) shares are up during Friday’s premarket session as the company has announced a definitive agreement to be acquired by ARCHIMED.
The deal will provide Esperion shareholders with $3.16 per share in cash at closing, plus potential milestone payments, which is contributing to the stock’s upward movement while broader markets experienced mixed results on Thursday.
Under the terms of the agreement, Esperion shareholders will receive $3.16 per share in cash at closing, along with the opportunity to participate in up to $100 million in contingent milestone payments based on future sales performance.
This acquisition represents a total equity value of approximately $1.1 billion, marking a significant premium of 58% over Esperion’s closing price on Apr. 30, 2026.
As of Dec. 31, 2025, cash and cash equivalents totaled $167.9 million compared to $144.8 million as of Dec. 31, 2024. Esperion ended the quarter with approximately 245.2 million shares of common stock outstanding, excluding 2.0 million treasury shares.
“With ARCHIMED’s support, we believe Esperion will be well positioned to advance our Vision 2040 strategy and continue addressing the global burden of cardiometabolic disease,” said CEO Sheldon Koenig.
Last month, Esperion announced the closing of its acquisition of Corstasis Therapeutics …
This post was originally published here
